Proceedings of the 12th Annual Scientific Meeting, Medical Faculty, Universitas Jenderal Achmad Yani, International Symposium on "Emergency Preparedness and Disaster Response during COVID 19 Pandemic" (ASMC 2021)

<Previous Article In Volume
Next Article In Volume>

Emerging Pharmacotherapies for COVID-19

Drugs Repurposing and Rationality

Authors
Evi Sovia
Corresponding Author
Evi Sovia
Available Online 24 July 2021.
DOI
10.2991/ahsr.k.210723.014How to use a DOI?
Keywords
COVID-19, SARS-CoV-2, repurposing, antiviral, immune based therapy
Abstract

The pandemic of coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), current an unparalleled challenge in terms of identifying successful prevention and treatment medications. Clinicians need reliable evidence due to the rapid pace of scientific discovery and clinical data provided by the large number of people infected with SARS-CoV-2. The present review was conducted to summarize the repurposing efficacy of the currently used drugs against COVID-19. Number of antiviral drugs such as remdesivir, favipiravir, chloroquine, hydroxychloroquine, ivermectin, lopinavir, ritonavir has shown inhibitory effects against the SARS-CoV-2 in-vitro as well as in clinical conditions. The immune based therapy like corticosteroids, tocilizumab, baricitinib, casirivimab, and bamlanvimab have shown some promise in more severe cases. Google Scholar, PubMed and SCOPUS were queried using a combination of the keywords “COVID-19,” SARS-CoV-2,” and “pharmacotherapy.” The type of studies that evaluated was clinical trial. Remdesivir has shown the best results and may now be an effective tool for reducing COVID-19 mortality, but more precise and potent antivirals against SARS-CoV-2 would be needed to stop current and/or potential coronavirus pandemics. While, immune based therapy using corticosteroids and anti-SARS- CoV-2 monoclonal antibodies may have their benefit in COVID-19 treatment.

Copyright
© 2021, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 12th Annual Scientific Meeting, Medical Faculty, Universitas Jenderal Achmad Yani, International Symposium on "Emergency Preparedness and Disaster Response during COVID 19 Pandemic" (ASMC 2021)
Series
Advances in Health Sciences Research
Publication Date
24 July 2021
ISBN
10.2991/ahsr.k.210723.014
ISSN
2468-5739
DOI
10.2991/ahsr.k.210723.014How to use a DOI?
Copyright
© 2021, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - CONF
AU  - Evi Sovia
PY  - 2021
DA  - 2021/07/24
TI  - Emerging Pharmacotherapies for COVID-19
BT  - Proceedings of the 12th Annual Scientific Meeting, Medical Faculty, Universitas Jenderal Achmad Yani, International Symposium on "Emergency Preparedness and Disaster Response during COVID 19 Pandemic" (ASMC 2021)
PB  - Atlantis Press
SP  - 54
EP  - 59
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.210723.014
DO  - 10.2991/ahsr.k.210723.014
ID  - Sovia2021
ER  -